Allogene Therapeutics (NASDAQ: ALLO)
Allogene Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Allogene Therapeutics Company Info
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
News & Analysis
Why Beam Therapeutics Stock Dipped Today
A clinical hold is weighing on the biotech's shares today.
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
A key gene-editing readout had Cathie Wood shuffling her portfolio.
Why Allogene Therapeutics Stock Is Getting Hammered Today
A possible safety issue is crushing the biotech's shares today.
4 Companies That Could Upend the Pharma Industry
Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.
Here's Why Allogene Therapeutics Is Roaring Higher Today
The development-stage biopharma reported encouraging, albeit early, data from an important pipeline program.
2 Big Biotech Stock Upgrades: Can They Reach These Targets?
Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.